Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $137 Billion
- Q3 2024
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 27,593 shares of VRDN stock, worth $574,486. This represents 0.46% of its overall portfolio holdings.
Number of Shares
27,593
Previous 27,484
0.4%
Holding current value
$574,486
Previous $358 Million
75.56%
% of portfolio
0.46%
Previous 0.27%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$99.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$92 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$80.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$78.1 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$71.7 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $830M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...